FDA Approves First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
WHY IT MATTERS
For the first time, adults with chronic HDV infection now have an FDA-approved treatment option, ending decades without any approved therapy for this serious liver disease.
The FDA has approved a new medicine called Hepcludex to treat chronic hepatitis delta virus (HDV) infection. HDV is a serious liver virus that only affects people who already have hepatitis B. This is the first FDA-approved treatment specifically for HDV, and it can be used in adults whose livers are not yet severely scarred or who have some scarring but stable liver function.
Today, the U.S. Food and Drug Administration approved Hepcludex (bulevirtide-gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis (advanced liver scarring) or with compensated cirrhosis.
YOU CAN ACT ON THIS
If you have chronic HDV infection, talk to your hepatologist or liver doctor immediately about whether Hepcludex is appropriate for you and how to access it.